Immuron Ltd
IMM-529
Clostridioides difficile infection
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for IMM-529 in Clostridioides difficile infection are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 13h ago
“Up to ~98k patients would be eligible if IMM-529 is positioned at the first recurrence.”